Liam F. Spurr, MD

Radiation oncology resident @MDAndersonNews | Alum: @UChiPritzker @BroadInstitute @GWtweets | 🔬: Radiotherapy, genomics, & tumor evolution

[Stephanie Dudzinski MD, PhD @StephDudzinski]

🌟PGY-2 @UTMDAnderson co-resident @LiamSpurrMD shows 🤗 data from SOAR✈️ Ph II RCT:
SBRT vs conventional fx re-irradiation in H&N cancer

- Pts prefer SBRT—> some of crossover
- SBRT has comparable LC & PROs
- SBRT w/ ⬇️ G3+ tox

Can’t wait for final results to come!
#ARS2026

[Stephanie Dudzinski MD, PhD @StephDudzinski]

So proud 🥹 of my @UTMDAnderson #RadOnc co-residents! 👏

🏆 3 Early Career Oncologist Awards: @Jordan_McD3, Dr. Kwong, Dr. Colson-Fearon

✈️ 4 Travel/Early Career Awards @Jane__Pearce, @CesarPMarquez1, @LiamSpurrMD, Dr. Gupta

Incredible showing at #ARS2026 🔥💪

New record?!

[Emma B. Holliday MD @DrEmmaHolliday]

Our residents and fellows are so lucky to learn from our world-famous pediatric rad onc faculty to take excellent care of our littlest patients 🩷

[Emma B. Holliday MD @DrEmmaHolliday]

Annual resident-med student mixer- 🚤. 🍻 and 🍗

Beautiful sunset, no Carl 🐊 sighting this year!

[ASTRO @ASTRO_org]

ASTRO is deeply disturbed by the inaccurate, inappropriate, and irresponsible NBC News piece on IORT. We feel this story harms care for breast cancer patients & have strongly rebutted it through our Breast Cancer Resource Panel & a letter from ASTRO CEO, Vivek S Kavadi, MD to NBC News.

Read each here:
Breast Resource Panel Statement
https://t.co/KU1jDQJnaf

Letter to NBC News from Dr. Vivek S. Kavadi
https://t.co/FxfoEtGI7R

[Sean Pitroda, M.D. @SeanPitroda]

Thread 1/14 🧵
New in @CCR_AACR: Our perspective on amphiregulin (AREG) as both a PREDICTIVE BIOMARKER and THERAPEUTIC TARGET following stereotactic radiotherapy (SBRT) in metastatic cancer.

What makes this clinically actionable? Let's dive in.

[Denise De la Cruz, Ed.D. @yogagirldd]

We are SO excited to welcome the @MDAndersonNews ☢️ #RadiationOncology #Residency #Classof2029 ✨ and our #RadOnc #fellows 🌟 today! 🤩 Happy New (Academic) Year, everyone! 🎉 @ChelseaPinnix @DrEmmaHolliday @ACKoongMDPhD @PrajnanDasMD

[Liam F. Spurr, MD @LiamSpurrMD]

Check out our new perspective in @NatureGenet exploring the role of #aneuploidy in predicting outcomes following treatment w/ checkpoint inhibitors & opportunities for therapeutic interventions

@SeanPitroda @rweichselbaum @UChicagoRadonc @UCCancerCenter

https://t.co/btPmrJHa4Z

[Sean Pitroda, M.D. @SeanPitroda]

🧵1/
Tumor aneuploidy—long viewed as a hallmark of cancer—is emerging as a key biomarker of immune resistance.
In our latest @NatureGenet Perspective, we explore how aneuploidy can guide immunotherapy decisions and shape future treatment strategies.
🔗 https://t.co/2U0vAhnkQG

[Liam F. Spurr, MD @LiamSpurrMD]

@BenjaminSchrank @NatRevImmunol @yarmo111 @nyulangone @BettyKimLab @preprintclub Congrats Ben!!

[Stephen V Liu, MD @StephenVLiu]

This is a major story from #ASCO25. Randomized phase 3 trial of time of day of immunotherapy infusion. Randomized to infusion before or after 3pm. Early infusion far superior: PFS 11.3 vs 5.7 HR 0.42, OS HR 0.45! Impactful, pragmatic, not costly. This should be a bigger story.

[JAMA Oncology @JAMAOnc]

Phase 3 oncology RCTs often report positive results based on alternative end points, but actual improvements in overall survival or quality of life are rare, highlighting need to prioritize these outcomes in future research & regulatory processes. #ASCO25 https://t.co/GRGe7FuLqm

[NonsparseOncologist @5_utr]

RCT Structured exercise for colon cancer

OS HR 0.63 (0.43 to 0.94)

Wow. Should we extrapolate to rectal also and send patients for this? @NiuSanford @SuyogCancer Seems like no downside really

https://t.co/bsmmYWB3VE

[Krishan Jethwa @KrishanJethwa]

🔥❓Is Pre-op Chemoradiation the new SoC for locally advanced gallbladder cancer❓🔥

🚨POLCA-GB🚨
T3-4 or N+ GB cancer
🔍Gem-Cis +- CRT

CRT Demonstrated:
✅⬆️OS, at median and with substantial separation at tail of curve (read: dcurability)
✅⬆️PFS
✅⬆️Objective response
✅No adverse safety signal

🔥Compelling argument that 🧨 (chemo + CRT) offers advantage for LA-gallbladder cancer, supporting its use in this population

#ASCO25

[Angel Montero Luis @Monthy_A]

Elderly, low-risk breast cancer patients have similarly OS and PFS with low rates of local recurrence, distant recurrence, and death from breast cancer whether treated with RT or HT + RT #radonc #bcsm https://t.co/Tq3aJI2ieX

[Liam F. Spurr, MD @LiamSpurrMD]

Check out our recent work studying the genomic profiles of inflammatory breast cancer #bcsm
@nlinmd

https://t.co/2A321pzXFB

[Fight Colorectal Cancer @FightCRC]

Save this video if you're preparing for radiation therapy!

We asked Dr. Nina Sanford (@NiuSanford), a GI Radiation Oncologist, what exactly #colorectalcancer patients can expect from radiation therapy. Did you know all of this about radiation?

Learn m... https://t.co/mJ3oDiKQ9t

[Udhayvir Grewal @UGrewalMD]

Potentially practice changing for locally advanced GB cancer. Phase III RCT (POLCAGB) of NACT vs NACRT—> better resection rates and OS!! @curecc #ASCO25

[Todd Aguilera MD PhD @aguilera_md]

Yesterday we treated our first patient on the Ph3 #ULTRAS trial—on board within 1 week of activation! Single-fraction SABR to liver mets from ENTSCC, NSCLC, CervSCC, and gastric/pancreatic ADC. @utswcancer @UTSW_RadOnc @Dr_AliHosni Excited to team up w/ partners and move fast!

[CircEP @CirculationEP]

Stereotactic arrhythmia radiotherapy (STAR) treats VT by locally increasing ERP, not increasing scar burden
#AHAJournals #Epeeps @pmjboyle @Alicardsdoc @SBRTCR @brianzenger @carmenbergom @JulieSchwarz14 @RentschlerLab
https://t.co/jJAOEwLjR4